J9352 – Injection, trabectedin, 0.1 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9352
- Long description
- Injection, trabectedin, 0.1 mg
- Short description
- Injection trabectedin 0.1mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1DChemotherapy- Added
- January 1, 2017
- Last change
- October 1, 2026 – Discontinued
- Termination date
- September 30, 2026
Frequently asked questions
What is HCPCS code J9352?
J9352 is a HCPCS Level II code for injection, trabectedin, 0.1 mg. It was discontinued on September 30, 2026.
Does Medicare cover J9352?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9341 – Injection, thiotepa (tepylute), 1 mg
- J9342 – Injection, thiotepa, not otherwise specified, 1 mg
- J9345 – Injection, retifanlimab-dlwr, 1 mg
- J9347 – Injection, tremelimumab-actl, 1 mg
- J9348 – Injection, naxitamab-gqgk, 1 mg
- J9349 – Injection, tafasitamab-cxix, 2 mg
- J9350 – Injection, mosunetuzumab-axgb, 1 mg
- J9351 – Injection, topotecan, 0.1 mg
- J9353 – Injection, margetuximab-cmkb, 5 mg
- J9354 – Injection, ado-trastuzumab emtansine, 1 mg
- J9355 – Injection, trastuzumab, excludes biosimilar, 10 mg
- J9356 – Injection, trastuzumab, 10 mg and hyaluronidase-oysk
- J9357 – Injection, valrubicin, intravesical, 200 mg
- J9358 – Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
- J9359 – Injection, loncastuximab tesirine-lpyl, 0.075 mg
- J9360 – Injection, vinblastine sulfate, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.